Intarcia boosts private cash with $1bn-plus Servier deal
This article was originally published in Scrip
Executive Summary
For Intarcia Therapeutics, which wanted to retain 100% of the domestic rights to its once-yearly diabetes drug, Servier turned out to be the best possible partner to commercialize ITCA 650 in foreign markets given the French pharmaceutical firm's long-standing aversion to the US market.
You may also be interested in...
Intarcia Raises $215m As NDA For ITCA 650 Slips To Fourth Quarter
Intarcia announced $215m in new equity financing and revised its NDA submission timeline for the second time since it reported positive Phase III results for ITCA 650 versus Januvia in mid-2015.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.